Inicio de la web del Complejo Hospitalario Universitario de Albacete

Saltar a contenidos
Decoracion. Fotomontaje de dos medicos observando una radiografia junto con el logotipo del Hospital.

Barra de navegación

Esta usted en:
Compartir en FacebookCompartir en Twitter
Aumentar tamao del texto..
Tamao normal del texto..
Disminuir tamao del texto..
Escuche el contenido de esta pgina. Se abrir una nueva ventana..
Publicaciones
  1. Ruiz-Moreno JM, Roura M; en representación del grupo del estudio Mypathway. Cost of myopic patients with and without myopic choroidal neovascularization. Arch Soc Esp Oftalmol. 2016 Feb 18. pii: S0365-6691(16)00016-2

  2. Flores-Moreno I, Arias-Barquet L, Vidal-Martí M, Muñoz-Blanco A, Rubio-Caso MJ, Ruiz-Moreno JM, Duker JS, Caminal JM. The Prevalence of Vitreomacular Interface Pathology in a Spanish Tertiary Hospital. Ophthalmologica. 2016 Feb 18.

  3. Peña-García P, Peris-Martínez C, Abbouda A, Ruiz-Moreno JM. Detection of subclinical keratoconus through non-contact tonometry and the use of discriminant biomechanical functions. J Biomech. 2016 Feb 8;49(3):353-63.

  4. Figueroa MS, Govetto A, Contreras I, Ruiz-Moreno JM, Del Valle FG, Plascencia RN, Medina JL. Reply. Retina. 2016 Jan;36(1)

  5. Balañá M, Ruiz-Moreno JM, Roura M; Study Group of Mypathway. National Study to Assess The Costs of Patients With High Myopia With and Without Choroidal Neovascularisation. Value Health. 2015 Nov;18(7)

  6. García-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F, García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. J Ophthalmol.

  7. García-Layana A, Figueroa MS, Araiz J, Ruiz-Moreno JM, Gómez-Ulla F,Arias-Barquet L, Reiter N. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept. Drugs Aging. 2015 Oct;32(10):797-807.

  8. Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Ruiz Moreno JM, Dugel P, Lotery A; FAME study group. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015 Sep;29(9):1240.

  9. Flores-Moreno I, Caminal JM, Arias-Barquet L, Rubio-Caso MJ, Catala-Mora J, Vidal-Martí M, Muñoz-Blanco A, Filloy A, Ruiz-Moreno JM, Duker JS, Arruga J. En face mode of swept-source optical coherence tomography in circumscribed choroidal haemangioma. Br J Ophthalmol. 2015 Jul 23.

  10. Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Ruiz Moreno JM, -Dugel P, Lotery A; FAME study group. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015 Sep;29(9):1173-80.

  11. Ruiz-Moreno JM, Montero JA, Araiz J, Arias L, García-Layana A, Carneiro A,Figueroa MS, Silva R. Intravitreal anti-vascular endothelial growth factortherapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina. 2015 Dec;35(12):2450-6

  12. Ruiz-Medrano J, Flores-Moreno I, Montero JA, Duker JS, Ruiz-Moreno JM.Morphologic features of the choroidoscleral interface in a healthy population using swept-source optical coherence tomography. Am J Ophthalmol. 2015 Sep;160(3):596-601.

  13. Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, Fernández I,García-Gutierrez MT, Ruiz-Moreno JM, Rocha-Sousa A, Ramkissoon YD, Harsum S,MacLaren RE, Charteris DG, Van Meurs JC, González-Sarmiento R, Pastor JC;Genetics on PVR Study Group. BAX and BCL-2 polymorphisms, as predictors ofproliferative vitreoretinopathy development in patients suffering retinaldetachment: the Retina 4 project. Acta Ophthalmol. 2015 Nov;93(7):e541-9.

  14. Figueroa MS, Ruiz-Moreno JM, Gonzalez del Valle F, Govetto A, de la Vega C, Plascencia RN, Contreras I, Medina JL. Long-term outcomes of 23-gauge pars plana vitrectomy with internal limiting membrane peeling and gas tamponade for myopic traction maculopathy: A Prospective Study. Retina. 2015 Sep;35(9):1836-43

  15. Ruiz-Medrano J, Flores-Moreno I, Peña-García P, Montero JA, Duker JS, Ruiz-Moreno JM. Asymmetry in macular choroidal thickness profile between both eyes in a healthy population measured by swept-source optical coherence tomography. Retina. 2015 Oct;35(10):2067-73.

  16. Ruiz-Moreno JM. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy]. Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:24-8.

  17. García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-Barquet L,Cabrera-López F, Figueroa MS. A review of current management of vitreomacular traction and macular hole. J Ophthalmol. 2015;2015:809640.

  18. Flores-Moreno I, Arias-Barquet L, Rubio-Caso MJ, Ruiz-Moreno JM, Duker JS,Caminal JM. En face swept-source optical coherence tomography in neovascular age-related macular degeneration. Br J Ophthalmol. 2015 Sep;99(9):1260-7.

  19. Copete S, Flores-Moreno I, Montero J, Duker JS, Ruiz-Moreno JM. Direct Comparison of Spectral-Domain and Swept-Source OCT in the Measurement of Choroidal Thickness in Normal Eyes.Br J Ophthalmol 2014;98:334-338 (FI: 2,809). A

  20. Jose Maria Caire, Sergio Recalde, Alvaro Velazquez, Laura Garcia-Garcia, Nicholas Reiter, Jaouad Anter, Patricia Fernandez-Robredo, Alfredo Garcia-Layana MD. On behalf of the Spanish Multi-center Group on AMD* *Members of the Spanish Multicenter Group on AMD: Miguel Ángel Zapata, José María Ruiz-Moreno, Carlos Cava, Rosa Coco, Lluís Arias, Clemencia Torrón, Oscar Ruiz-Moreno, Henar Heras, María Isabel López-Gálvez, Juan Donate, Miguel Ángel de la Fuente, Ana María Gómez-Ramírez, Rosa Sanabria. Growth of Geographic Atrophy on Fundus Autofluorescence and Polymorphisms of CFH, CFB, C3, FHR1–3, and ARMS2 in AgeRelated Macular Degeneration. JAMA Ophthalmology 2014;132:528-534. (FI: 4,488). A

  21. Montero JA, Yanez-Castro G, Sanchis-Merino ME, Ruiz-Moreno JM. Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy. BMJ Case Rep. 2014 Feb 7;2014. A - Jorge Ruiz-Medrano, Ignacio Flores-Moreno, Pablo Peña-García, Javier A Montero, Jay S Duker, José M Ruiz Moreno. Macular choroidal thickness profile in a healthy population measured by Swept-Source Optical Coherence Tomography. Invest Ophthalmol Vis Sci 2014;55:3532-42 (FI: 3,661). A

  22. Ignacio Flores Moreno, Francisco Lugo, Jay S Duker, Jose M Ruiz-Moreno. The relationship between Axial Length and Choroidal Thickness in eyes with High Myopia. Am J Ophthalmol 2013;155:341-319 (FI: 4,021). A

  23. José M Ruiz-Moreno, Iñaki Flores-Moreno, Francisco Lugo, Jorge Ruiz-Medrano, Javier A Montero, Masahiro Akiba. Macular choroidal thickness in normal pediatric population measured by Swept-Source Optical Coherence Tomography. Invest Ophthalmol Vis Sci 2013;54:353-359 (FI:3,661). A

  24. Rufino M Silva, Jose M Ruiz-Moreno, Francisco Gómez-Ulla, Javier Montero, Tatiana Gregorio, Maria L Cachulo, Isabel A Pires, Jose G Cunha-Vaz, Joaquim N Murta.Photodynamic therapy for chronic central serous chorioretinopathy. A 4-year follow-up. Retina 2013;33:309-315. (FI: 3,177). A

  25. Pastor-Idoate S, Rodríguez-Hernandez I, Rojas J, Fernandez I, Garcia-Gutierrez MT, Ruiz-Moreno JM, RochaSousa A, Ramkisson Y, Harsum S, MacLaren RE, Charteris DG, VanMeurs JC, González-Sarmiento R, Pastor J. C and the Genetics for PVR Study Group.The p53 codon 72 polymorphism (rs1042522) is associated with Proliferative Vitreoretinopathy. Retina 4 project. Ophthalmology 2013;120:623-628. (FI: 6,170). A

  26. Javier A Montero, Jose M Ruiz-Moreno, Eugenia Sanchis-Merino, Santiago Perez-Martin. Systemic betablockers may reduce the need for repeated intravitreal injections in patients with wet age related macular degeneration treated by bevacizumab.Retina 2013;33:508-512. (FI: 3,177). A

  27. Jimena Rojas, Itziar Fernandez, Jose C Pastor, Robert E MacLaren, Yashim Ramkissoon, Steven Harsum, David G Charteris, Jan C Van Meurs, Sankha Amarakoon, Jose M Ruiz-Moreno, Amandio Rocha-Souza, Maria Brion, Angel Carracedo, for the Genetics on PVR Study Group.A Genetic Case-control Study Confirms The Implication Of SMAD7 And TNF Locus In The Development Of Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci 2013;54:1665-78. (FI:3,661). A

  28. José M Ruiz-Moreno, Luis Arias, Javier Araiz, José García-Arumí, Javier A Montero, David P Piñero. SD-OCT study of macular structure as prognostic and determining factor for macular hole surgery outcome.Retina 2013;33:1117-1122. (FI: 3,177). A

  29. JM Ruiz-Moreno, María I López-Gálvez, Javier A Montero, José C Pastor. Intravitreal bevacizumab in myopic neovascular membranes: 24-months results.Ophtahlmology 2013;120:1510-1. (FI: 6,170). A

  30. Anna Sala-Puigdollers, Itziar Fernandez, Rosa Coco, Maria R Sanabria, Enrique Rodriguez de la Rúa, José M Ruiz-Moreno, Amparo Navea, Marta S Figueroa, José C Pastor. External validation of existing formulas to predict the risk of developing proliferative vitreoretinopathy.Retina 2013;33:1519-27 (FI: 3,177) A

  31. Joaquín Jordán, José M Ruiz-Moreno. Advances in the undestanding of retinal drug disposition and the role of Subdirección General de Evaluación y Fomento de la Investigación CURRICULUM VITAE Página 5 2015 blood-ocular barrier transporters.Expert Opin Drug MetabToxicol. 2013;9:1181-92 (FI: 2,934). A

  32. Javier A Montero, Amaparo A Merino-Iglesias, Santiago Pérez-Martin, José M Ruiz-Moreno. Intravitreal drug dispersion and needle gauge. Acta Ophthalmol 2013 Jul 26. (FI: 2,512). A

  33. Ignacio Flores-Moreno, Jorge Ruiz-Medrano, Jay S Duker, José M Ruiz-Moreno. The relationship between retinal and choroidal thickness and visual acuity in highly myopic eyes.Br J Ophthalmol 2013;97:1010-3 (FI: 2,809). A

  34. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 2013;97:1447-50. (FI: 2,809). A

  35. Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F; RESTORE Study Group (Ruiz Moreno JM). Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol 2013;131:1339-47 (FI: 4,488). A

  36. Pastor-Idoate S, Rodríguez-Hernández I, Rojas J, Fernández I, García-Gutiérrez MT, Ruiz-Moreno JM, RochaSousa A, Ramkissoon Y, Harsum S, Maclaren RE, Charteris D, Vanmeurs JC, González-Sarmiento R, Pastor JC; Genetics on PVR Study Group. The T309G MDM2 Gene Polymorphism Is a Novel Risk Factor for Proliferative Vitreoretinopathy. PLoS One. 2013 Dec 9;8(12): (FI: 3,534). A

  37. Martínez-Barricarte R, Recalde S, Fernández-Robredo P, Millán I, Olavarrieta L, Viñuela A, Pérez-Pérez J, García-Layana A, Rodríguez de Córdoba S, Zapata MÁ, Ruiz-Moreno JM, Coco R, Arias L, Torrón C, RuizMoreno O, Heras H, López-Gálvez MI, Donate J, de la Fuente MÁ, Gómez-Ramírez AM, Sanabría R. Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53:1087-94. (FI:3,441). A

  38. JM Ruiz-Moreno, JA Montero, L Jonet, JC P Jeanny, F Behar-Cohen. Histopathology of peripapillary choroidal neovascularization. Ophthal Surg Las Im 2012;43:e22-6.(FI: 1,464). A

  39. Jose M. Ruiz-Moreno, Javier A. Montero, Luis Arias, Javier Araiz, Francisco Gomez-Ulla, Rufino Silva, David P. Piñero. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol 2012; e82-e83. (FI: 2,345). A

  40. Sergio Copete, Jose M Ruiz-Moreno, Carlos Cava, Javier A Montero. Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2012;250:803-808 (FI: 1,932). A

  41. JM Ruiz-Moreno, F Lugo, JA Montero, DP Piñero.Restoration of macular structure as the determinig factor for macular surgery outcome. Graefes Arch Clin Exp Ophthalmol 2012;250:1409-1414. (FI: 1,932). A -Javier Montero, JM Ruiz-Moreno. In vitro actibacterial activity of endotamponading gases. Aceptado en Acta Ophthalmol (FI: 2,345). A

  42. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group. Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema.Ophthalmology 2012;119:2125-2132 (FI: 5,563). A

  43. JA Montero, JM Ruiz-Moreno, M Fernandez-Muñoz. Spectral domain OCT findings in acute posterior multifocal placoid pigment epitheliopathy. Ocul Immunol and Inflammation 2011;19:48-50. (FI: 1,250). A

  44. J. Fernando Arevalo, Alfredo Adan, Maria H. Berrocal, Juan V. Espinoza, Mauricio Maia, Lihteh Wu, Jose A. Roca, Hugo Quiroz-Mercado, Jose Ma. Ruiz-Moreno, Martin A. Serrano, for the Pan-American Collaborative Retina Study Group (PACORES)*. Intravitreal Bevacizumab for Inflammatory Choroidal Neovascularization: Results from the Pan-American Collaborative Retina Study Group at 24 Months. Retina 2011;31:353-363 (FI: 2,812). A

  45. JM Ruiz-Moreno, JA Montero. Sliding macular fold following retinal detachment surgery. Graef Arch Clin Exp Ophthalmol 2011;249:301-303. (FI: 2,170). A

  46. Ruiz-Moreno JM, Montero JA, Amat P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011;249:595-599. (FI: 2,170). A

  47. Casas-Llera P, Ruiz-Moreno JM, Alió JL. Retinal imaging after corneal inlay implantation. J Cataract Refract Surg 2011;37:1729-1731. (FI: 2,264). A

  48. P Mitchell, F Bandello, U Schmit-Erfurth, et al.The RESTORE study. Ophthalmology 2011;118:615-625. (FI: 5,454) A

  49. JM Ruiz-Moreno, María I López-Gálvez, Juan Donate, Francisco Gomez-Ulla, José García-Arumí, Alfredo García-Layana, Inmaculada Sellés, Juan Reche, Javier A Montero, Belen Pazos, Miguel A. Zapata, José C Pastor. Myopic choroidal neovascularization. Ophtahlmology 2011;118:2521-2523. (FI: 5,454). A

  50. Javier A Montero, José M Ruiz-Moreno, Marta Fernandez-Muñoz. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy. Eur J Ophtalmol 2011;21:503-505. (FI: 0,965). A

  51. Javier Montero, JM Ruiz-Moreno, E Sanchis-Merino. Intravitreal ranibizumab, with o without filter?. Acta Ophthalmol 2011; Oct 19. (FI: 2,629). A

  52. Rufino Silva, JM Ruiz-Moreno, PC Rosa, A Carneiro, J Nascimento, LF Rito, ML Cachulo, F Carvalheira, JN Murta. Intravitreal ranibizumab for myopic choroidal neovacularization: 12-months results. Retina 2010;30:407-412 (FI: 2,774). A

  53. Javier A Montero, Jose M Ruiz-Moreno. Treatment of choroidal neovascularization in high myopia. Curr Drugs Targets 2010;11:630-644. (FI: 4,187). A

  54. Sainz-Gómez C, Fernández-Robredo P, Salinas-Alamán A, Montañés JM, Escudero Berasategui JM, GuillénGrima F, Ruiz-Moreno JM, García-Layana A. Prevalence and causes of bilateral blindness and visual impairment among institutionalized elderly people in Pamplona, Spain. Eur J Ophthalmol 2010;20:442-450. (FI: 0,980). A

  55. José Mª Ruiz-Moreno, Francisco L Lugo, Felix Armadá, Rufino Silva, Javier A Montero, Fernando Arevalo, Luis Arias, Francisco Gómez-Ulla. Photodynamic therapy for chronic central serous chorio-retinopathy”. Acta Ophthalmol Scan 2010;88:371-376. (FI: 2,809). A

  56. Javier A Montero, Jose M Ruiz-Moreno, Marta Fernandez-Muñoz, M Camino Gonzalez-Martinez. Asymptomatic oculocardiac reflex during phacoemulsification. Acta Ophthalmol Scan 2010;88:52-53. (FI: 2,809). A

  57. JM Ruiz-Moreno, Javier A Montero.Intravitreal bevacizumab to treat myopic choroidal neovacularization: two years outcome. Graef Arch Clin Exp 2010;248:937-941. (FI: 2,158). A

  58. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146. (FI: 5,017). A

  59. AM Carneiro, R Silva, MJ Veludo, A Barbosa, JM Ruiz-Moreno, MS Falcao, EM Brandao, FM Falcao-Reis. Ranibizumab treatment for choroidal neovascularization from causes other than Age-relataed macular degeneration and pathological myopia. Ophthalmologica 2010; 225:81-88 (FI: 1,303). A

  60. Jose María Ruiz-Moreno, Javier A Montero, Luis Arias, Javier Araiz, Francisco Gómez-Ulla, Rufino Silva, MD, David P Piñero, MSc. Twelve months outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30:1609-1615. (FI: 2,774). A

  61. J Rojas, I Fernandez, JC Pastor, MT Garcia-Gutierrez, MR Sanabria, M Brion, RM Coco, JM Ruiz-Moreno, J Garcia-Arumi, J Elizalde, M Ruiz-Miguel, JM Gallardo, RM Corrales, A Carracedo. A Strong Genetic Association in the TNF Locus with Proliferative Vitreoretinopathy. The Retina 4 Project. Ophthalmology 2010;117:2417-2423. (FI: 5,017). A

 

 

Pie de página

Complejo Hospitalario Universitario de Albacete. Webmaster. Todos los derechos reservados. Nota Legal.


HTML 4.01 Transitional válido - CSS Válido - Icono de conformidad con el Nivel Triple-A, de las Directrices de Accesibilidad para el 	Contenido Web 1.0 del W3C-WAI - Validado por TAW